Home > Boards > US Listed > Computers - Hardware > Anixa Biosciences (ANIX)

US Patent & Trademark Office Issues Patent on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Paullee Member Profile
 
Followed By 18
Posts 2,780
Boards Moderated 0
Alias Born 11/25/03
160x600 placeholder
Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates PR Newswire (US) - 2/16/2021 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/5/2021 4:46:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/1/2021 9:00:53 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/28/2021 1:01:00 PM
Anixa Biosciences to Present at the B. Riley Oncology Investor Conference PR Newswire (US) - 1/13/2021 8:30:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 1/7/2021 4:18:55 PM
Annual Report (10-k) Edgar (US Regulatory) - 1/7/2021 4:17:11 PM
Anixa Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference PR Newswire (US) - 1/5/2021 8:30:00 AM
Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine PR Newswire (US) - 12/21/2020 8:30:00 AM
Anixa Biosciences Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing PR Newswire (US) - 12/14/2020 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/1/2020 3:31:05 PM
Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology PR Newswire (US) - 12/1/2020 9:00:00 AM
Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine PR Newswire (US) - 11/23/2020 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2020 5:06:52 PM
Anixa Biosciences to Host Conference Call to Provide Update on Programs PR Newswire (US) - 10/27/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/16/2020 10:31:03 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2020 9:30:14 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/11/2020 11:59:25 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 9/8/2020 4:31:32 PM
Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference PR Newswire (US) - 9/8/2020 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:46:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:38:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:28:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:18:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/17/2020 4:08:03 PM
Paullee   Wednesday, 04/17/19 09:00:49 AM
Re: None
Post # of 697 
US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology
PR Newswire PR Newswire•April 17, 2019
SAN JOSE, Calif., April 17, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 10,259,855. This is the first patent covering Anixa's CAR-T cancer treatment technology.

Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt. Dr. Conejo-Garcia is the Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is a Senior Postdoctoral Fellow in The Wistar Institute's Vaccine & Immunotherapy Center. The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.

Dr. Amit Kumar, Anixa's Chairman, President and CEO, stated, "The claims of this patent were allowed in January of this year as noted in a previous announcement, and we are pleased that this key patent has now issued. Those interested in reviewing the patent can now read the content." Dr. Kumar continued, "This technology takes advantage of specific hormone–hormone receptor biology to address malignancies and may hold promise to be the one of the first successful CAR-T therapies against solid tumors. While our initial focus is the treatment of ovarian cancer, the technology covered by the patent is broad and may also be effective in treating other solid tumors by exploiting an anti-angiogenesis mechanism of action. Anixa and its research and clinical development partner, the Moffitt Cancer Center, hope to file an IND application for this therapy later this year.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences